SCHEMBL3219376

SCHEMBL3219376

CCOC(=O)CN(C(=O)Oc1ccc(OC)cc1)c1cc(C)c(Oc2ccc(OC)c(C(C)CC)c2)c(C)c1

nearest known ligand 0.41

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.38
PPARG P37231 1/20 0.36
THRB P10828 6/20 0.35
THRA P10827 5/20 0.35
RORC P51449 1/20 0.34
USP2 O75604 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
LMNA P02545 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3227821 0.93 THRB (0.41) ALDH1A1PPARGTHRBTHRARORC
SCHEMBL3226718 0.93 THRB (0.37) ALDH1A1THRBTHRARORC
SCHEMBL3226111 0.91 THRB (0.43) ALDH1A1PPARGTHRBTHRARORC
SCHEMBL3227804 0.88 THRB (0.39) ALDH1A1PPARGTHRBTHRARORC
SCHEMBL3707589 0.85 THRB (0.38) THRBTHRARORCUSP2LMNA
SCHEMBL3217778 0.84 RORC (0.52) ALDH1A1PPARGTHRBTHRARORC
SCHEMBL3227188 0.84 THRB (0.46) ALDH1A1THRBTHRARORC
SCHEMBL3222511 0.80 THRB (0.47) PPARGTHRBTHRARORC
SCHEMBL3221348 0.79 THRB (0.48) ALDH1A1PPARGTHRBTHRARORC
SCHEMBL3963181 0.78 RORC (0.35) THRBTHRARORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420851-B2 Selective TR-β 1 agonist CADILA HEALTHCARE LIMITED (IN) 2013-04-16 US claimed
US-20100048550-A1 SELECTIVE TR-BETA 1 AGONIST CADILA HEALTHCARE LIMITED (IN) 2010-02-25 US claimed
EP-2079678-A2 SELECTIVE TR-BETA 1 AGONIST Cadila Healthcare Limited (IN) 2009-07-22 EP claimed
WO-2008062469-A2 SELECTIVE TR-BETA 1 AGONIST CADILA HEALTHCARE LIMITED (IN) 2008-05-29 WO claimed
US-8420851-B2 Selective TR-β 1 agonist CADILA HEALTHCARE LIMITED (IN) 2013-04-16 US disclosed
EP-2079678-B1 SELECTIVE TR-BETA 1 AGONIST CADILA HEALTHCARE LTD (IN) 2012-12-19 EP disclosed
US-20100048550-A1 SELECTIVE TR-BETA 1 AGONIST CADILA HEALTHCARE LIMITED (IN) 2010-02-25 US disclosed
EP-2079678-A2 SELECTIVE TR-BETA 1 AGONIST Cadila Healthcare Limited (IN) 2009-07-22 EP disclosed
WO-2008062469-A2 SELECTIVE TR-BETA 1 AGONIST CADILA HEALTHCARE LIMITED (IN) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048550-A1 SELECTIVE TR-BETA 1 AGONIST THRB, THRA, TSHR ALDH1A1 1801/4885PPARG 104/4885THRB 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.